1. Introduction
===============

Evolutionary and population genetic processes in rapidly evolving viruses can be highly dynamic even on human observable time-scales. Quantifying these dynamics and testing how ecology and host immune responses shape them is a major objective of phylodynamic analyses. Coalescent approaches, for example, allow inferring changes in population size through time from genealogies ([@vew023-B5]), and recent modelling advances have demonstrated the ability to incorporate ecological complexities, such as vector dynamics and spatial structure, that can affect the shape of viral genealogies ([@vew023-B26]). To assess changes in the tempo or mode of sequence evolution, most modelling efforts focus on variation among branches, either by accommodating specific prior hypotheses (e.g. clade-specific evolutionary rates modelled according to different hosts, see [@vew023-B39]) or by adopting flexible approaches that allow identifying the changes. Both approaches are available to detect or test variation in molecular clock rates ([@vew023-B3]; [@vew023-B39]) and variation in non-synonymous/synonymous substitution rate ratios (*dN*/*dS*, see [@vew023-B40]).

Identifying changes in *dN*/*dS* allows uncovering heterogeneity in selective pressure. In order to examine how such patterns vary in HIV-1 evolution over the course of a single infection, [@vew023-B9]) proposed an approach that models evolutionary shifts in the codon substitution process that cut across all lineages at a specific time point in a time-calibrated genealogy. We have recently presented a Bayesian implementation of such a time-inhomogeneous model that generalizes 'epoch' specifications to any discrete substitution process in an unknown evolutionary history, including, for example, phylogeographic processes ([@vew023-B1]). The epoch model allows specifying an arbitrary sequence of continuous-time Markov chain (CTMC) models through time while appropriately accommodating phylogenetic uncertainty. Likelihood computations under an epoch scenario require matrix convolution which adds to the high computational burden associated with fitting high-state space models to relatively large data sets. To considerably speed up these calculations, we have implemented massively parallel likelihood computations on multi-core devices such as graphics processing units.

In order to test prior hypotheses about the viral divergence stabilization observed in the AIDS stage of HIV-1 infection, we previously applied epoch modelling to extensively sampled sequence data over the time course of infection in several individuals ([@vew023-B1]). Specifically, we conditioned on the progression time for each patient, which represents the time at which the CD4+ T-cell counts drop below 200 cells/μl ([@vew023-B37]), to partition the evolutionary history into 2 intervals (the asymptomatic stage and the AIDS stage). By estimating *dN*/*dS* in independent codon substitution models associated with both epochs, we found a generally lower selective pressure on the viral population after progression time (in the AIDS stage). We interpreted this pattern as support for the 'immune relaxation hypothesis', which attributes the lower selective pressure to a damaged immune stage in the AIDS stage ([@vew023-B37]).

Although we were able to address this hypothesis using an epoch model with prior-determined transition times, disease progression may not necessarily follow a discrete two-step process. In fact, CD4+ T-cell counts on which the progression times are based generally decrease continuously throughout infection history, and inversely correlated with this, the viral load increases over time. If the evolutionary process is correlated with disease progression, it may be hypothesized that evolutionary parameters will follow the evolution of clinical parameters. In general, this calls for a framework to test potential predictors of the evolutionary process through time. For independent realizations of the evolutionary process (e.g. HIV-1 evolution in different patients), we have previously demonstrated the ability to estimate the support and contribution of explanatory variables to evolutionary parameters in an integrated Bayesian framework ([@vew023-B7]; [@vew023-B30]).

Although estimating *dN*/*dS* has proven useful in an epoch context ([@vew023-B1]), this only allows us to detect changes in selection dynamics. Intrahost viral evolution in persistent infections may also be influenced by factors that impact the underlying mutation rate or generation rate, such as variation in replication rates which was shown to be associated with differences in HIV-1 disease progression among patients ([@vew023-B21]), or HIV-1 storage in latently infected cells which may explain differences in evolutionary rate within and between patients ([@vew023-B35]). Disentangling these factors from selection forces requires a separate estimate of synonymous and non-synonymous substitution rates. In a fixed-tree molecular clock framework this may be achieved by codon modelling approaches aimed at estimating absolute rates of synonymous and non-synonymous substitution ([@vew023-B28]). In Bayesian inference approaches that accommodate phylogenetic uncertainty, the computational burden associated with codon models has restricted their application to relatively large datasets. This has motivated the development of different post-hoc procedures ([@vew023-B21]) and nucleotide-based counting proxies ([@vew023-B23]). While these approximations aim to quantify synonymous and non-synonymous substitution rates, they do not treat these quantities as model parameters and are therefore less suitable to extend to formal hypothesis testing procedures. With the current ability to considerably speed up likelihood calculations ([@vew023-B31]), massively parallel computation is now stimulating further codon model development in the Bayesian framework.

Here, we use an implementation of the Muse & Gaut (MG94) codon substitution model ([@vew023-B24]) in BEAST ([@vew023-B4]) to estimate synonymous and non-synonymous substitution rates. We adopt the approach in an epoch setting and further extend it to accommodate potential predictors of the substitution process using generalized linear modelling. We employ this framework to identify the support and contribution of various predictors of synonymous and non-synonymous substitution rates in intrahost HIV evolution. We do not find sufficient signal in separate analyses of eight different patients, but when jointly estimating predictor support and effect size, we find that progression time remains the best explanatory variable for non-synonymous rate variation despite the fact that we also consider CD4+ T-cell count and viral load measurements.

2. Methods
==========

2.1 Codon substitution modelling
--------------------------------

Our approach builds on the standard MG94 codon substitution model ([@vew023-B24]), which is parameterized in terms of a synonymous ($\alpha$) and non-synonymous ($\beta$) substitution rate by defining a CTMC infinitesimal rate matrix $\mathbf{Q} = \left\{ q_{ij} \right\}$ with the following off-diagonal entries: $$q_{ij} = \begin{cases}
{\alpha\kappa\pi_{j}} & \left. i\rightarrow j\,\text{is}\, a\,\text{one} - \text{nucleotide}\,\text{synonymous}\,\text{transition} \right. \\
 & {\text{ from}\,\text{codon}\, i\,\text{to}\, j.} \\
{\alpha\pi_{j}} & \left. i\rightarrow j\,\text{is}\, a\,\text{one} - \text{nucleotide}\,\text{synonymous}\,\text{transversion} \right. \\
 & {\text{ from}\,\text{codon}\, i\,\text{to}\, j.} \\
{\beta\kappa\pi_{j}} & \left. i\rightarrow j\,\text{is}\, a\,\text{one} - \text{nucleotide}\,\text{non} - \text{synonymous} \right. \\
 & {\,\text{transition from}\,\text{codon}\, i\,\text{to}\, j.} \\
{\beta\pi_{j}} & \left. i\rightarrow j\,\text{is}\, a\,\text{one} - \text{nucleotide}\,\text{non} - \text{synonymous} \right. \\
 & {\,\text{transversion from}\,\text{codon}\, i\,\text{to}\, j.} \\
0 & {\text{otherwise},} \\
\end{cases}$$ where *κ* is the transition--transversion rate and $\pi_{j\, j = 1,\ldots,61}$ denotes the frequency of the target codon.

We fit this codon model in a Bayesian framework and use Markov chain Monte Carlo (MCMC) integration to obtain a sample from the posterior distribution of model parameters ([@vew023-B4]). Because BEAST infers trees in time-units (e.g. using tip or node calibrations), substitution model matrices are generally normalized (to one substitution per site per unit time) and scaled by an estimable overall evolutionary rate parameter into the time units of the tree. In order to estimate absolute rates of synonymous and non-synonymous substitution rates, we perform a normalization that gives rise to  α + β  expected substitutions per site per year.

2.2 Epoch and general linear modelling
--------------------------------------

In order to identify predictors of changes in $\alpha$ and $\beta$ through time, we first embed the codon substitution process into an epoch setting ([@vew023-B1]). This setting posits that the substitution process is homogeneous within an epoch of time, but may change across epochs. To construct these epochs, we set, without loss of generality, the time of the most recent sequence sample from each patient to 0 and let the remaining $M - 1$ sampling-times define transition times $T_{1},\ldots,T_{M - 1}$, where we assume that time flows backwards, that is from the tips towards the MRCA. Together with $T_{M} = \infty$, the ordered times $T_{0} < T_{1} < \cdots < T_{M}$ define the boundaries of *M* epochs, such that epoch $m$ begins at time $T_{m - 1}$ and ends at time $T_{m}$. Note that the last epoch extends to $\infty$, but with the evolutionary history only extending to the MRCA.

For each of the *M* epochs, we associate a conditionally independent, infinitesimal rate matrix $\mathbf{Q}_{m} = \mathbf{Q}_{m}(\alpha_{m},\beta_{m})$ with $m = 1,\ldots,M$ that depends on epoch-specific synonymous $\alpha_{m}$ and non-synonymous $\beta_{m}$ rates. Then, for any two arbitrary times $t_{u} \leq t_{v}$ under this time-inhomogeneous process, we can compute the matrix of finite-time transition probabilities $$\mathbf{P}(t_{u},t_{v}) = \underset{m = 1}{\prod\limits^{M}}\,\text{exp}\,{\{{\mathbf{Q}_{m}{\lbrack{\min{({t_{v},T_{m}})}}}}} - {{{\max{({t_{u},T_{m - 1}})}}\rbrack}^{+}\}},$$ where ${\lbrack \cdot \rbrack}^{+} = \text{max}{({\cdot ,0})}$. While the computational cost of [Equation (2)](#E2){ref-type="disp-formula"} appears high, it is important to note that when the time-interval $\lbrack{t_{u},t_{v}}\rbrack$ does not intersect with a given epoch $m\prime$, $${\lbrack{\min{({t_{v},T_{m^{\prime}}})} - \max{({t_{u},T_{m^{\prime} - 1}})}}\rbrack}^{+} = 0,\,\text{and }\,\text{exp}\,{\{{\mathbf{Q}_{m\prime} \times 0}\}} = \mathbf{I},$$ where **I** is the identity matrix and, as such, no matrix-exponentiation nor matrix-multiplication is required for that epoch. Second, we parameterize $\alpha_{m}$ and $\beta_{m}$ as log-linear functions of potential predictors: $$\text{log}\,\alpha_{m} = \mu_{\alpha} + \mathbf{X}_{m}{({\theta_{\alpha} \odot \delta_{\alpha}})},\,\text{and }\,\text{log}\,\beta_{m} = \mu_{\beta} + \mathbf{X}_{m}{({\theta_{\beta} \odot \delta_{\beta}})},$$ where *μ~k~* is the grand-mean rate (on the log-scale) for $k \in \left\{ \alpha,\beta \right\}$, $\mathbf{X}_{m} = (X_{m1},\ldots,X_{mP})$ are *P* predictor values for epoch *m*, $\theta_{k} = {(\theta_{k1},\ldots,\theta_{kP})}^{T}$ quantify the contribution of each predictor to rate *k*, $\delta_{k} = {(\delta_{k1},\ldots,\delta_{kP})}^{T}$ are binary indicator variables that model the in-/exclusion of the predictor and $\odot$ is the component-wise product operation. To ensure that *μ~k~* quantifies the average rate across all epochs, we standardize the predictor values such that $(X_{1p},\ldots,X_{Mp})$ has mean 0 and standard deviation 1 for all quantifiable entries across $p = 1,\ldots,P$. Never quantifiable values may arise, for example, in the last epoch when predictors are functions of measurements taken at the sampling-time that demarcates the end of an epoch. For such predictors, we fix *X~Mp~* = 0 after standardization, so that $\text{log}\,\alpha_{M} = \mu_{\alpha}$ and $\text{log}\,\beta_{M} = \mu_{\beta}$.

To complete our prior specification, we assume that: $$\begin{array}{l}
{(\mu_{\alpha},\mu_{\beta}) \sim \text{MVN}\left( {0,1000 \times \mathbf{I}} \right),} \\
{\theta_{k} \sim \text{MVN}\left( {0,\frac{1}{7} \times \mathbf{I}} \right)\,\text{for}\,\text{all}\, k,\,\text{and}} \\
{\delta_{kp} \sim \text{Bernoulli}(q)\,\text{for}\,\text{all}\, k\,\text{and}\, p,} \\
\end{array}$$ where $\text{MVN}{({\cdot , \cdot})}$ signifies a multivariate normal distribution with given mean and variance and *p* is a prior inclusion probability. These priors incorporate the belief that most predictors will only have a modest impact on the evolutionary rate, but we wish to remain uninformative about its overall size through the grand-means. We select *q* such that there exists a 50% prior probability that no predictor is included in the model. Augmenting the GLM parameterisation with binary indicator variables for the predictors and their associated prior specification allows for a Bayesian stochastic search variable selection ([@vew023-B22]) procedure, which estimates posterior probabilities of inclusion or exclusion of a particular predictor in [Equation (4)](#E4){ref-type="disp-formula"} and allows us to readily compute Bayes factor support. In our analyses, we summarize mean and the 95% highest posterior density interval for the conditional effect size, which is the size of the effect (on log scale) conditional on the effect being included in the model ($\theta_{kp}|\delta_{kp} = 1$).

2.3 Sequence data and predictors
--------------------------------

We re-analyse extensively serially sampled *env* C2V5 sequences from eight patients throughout their infection starting close to the time of seroconversion ([@vew023-B29]). We do not consider one particular patient from the original study (patient 11) for which no data were available after progression time. The sequence data consist of the C2-V5 region of the HIV-1 *env* gene sequences collected in a longitudinal manner over a 6--13.7-year period, with a minimum of 5 and a maximum of 15 measurements per patient. In total, the data constitutes 1,300 sequences and 106 separate time points.

Most sampling times were associated with CD4+ T-cell counts and viral load (VL) ([Supplementary Fig. 1](#sup1){ref-type="supplementary-material"}), which we use as predictors in two different ways upon log transformation: either as the mean of the measurements at two boundaries of each epoch (*mean CD4* and *mean VL*) or as the difference between the two boundary values (*ΔCD4* and *ΔVL*). We also use the progression time as predictor, which is encoded as a binary indicator (in log space, with the same estimable effect size for each epoch prior to this time). In this sense, it may be more appropriate to refer to this as infection stage predictor. Furthermore, we consider several sampling characteristics as predictors such as the number of sequences sampled (the mean number of sequences sampled at both boundaries), the time since seroconversion (measured from the midpoint of the epoch) and the time length for each epoch (*epoch time*).

![Predictor inclusion probabilities for each predictor and each patient. All predictor inclusion probabilities estimated separately from each patient-specific viral population are summarized into a stacked bar plot. The bar plot on the left and right represents the summed inclusion probabilities for predictors of $\alpha$ and $\beta$~,~ respectively. The vertical dashed line represents eight times the prior inclusion probability used in each individual analysis.](vew023f1p){#vew023-F1}

Finally, we design a way to include effective population size change ($\Delta N_{e}$) over the epoch as a predictor for the sequence evolutionary parameters. For this purpose, we employ the recently developed Bayesian Skygrid model ([@vew023-B8]) and match the grid intervals to our epoch structure. We incorporate the difference in log *N*~e~ at the boundaries of the closed intervals as a predictor in our GLM design matrix. We opt to standardize predictors in our GLM approach and implement a dynamic standardization mechanism for the predictors in the design matrix because the log *N*~e~-based predictors are continuously updated during the MCMC. We note that the use of parameter estimates of the tree-generative model as predictors for the sequence evolutionary process informing the tree may be problematic. Initial explorations indeed indicated that this leads to an identifiability problem for the tree prior and sequence evolutionary parameters. To avoid this, we use an empirical set of trees, estimated by a standard nucleotide sequence analysis in BEAST, and average over this distribution while estimating population size and sequence evolutionary parameters.

Several observations are missing for the CD4 and VL variables, specifically for the datasets for patients 3, 7, 8 and 9. We used a feed-forward neural network with one hidden layer with ten nodes to impute those values. This graph of interconnected nodes (neurons) is capable of learning by adjusting the weights of the paths connecting its inputs to outputs ([@vew023-B2]). In the datasets for patients 3 and 9 several observations are missing for both predictors, and since the neural network is trained using backward propagation of errors, we recode all the values to fall between $( - 1,1)$ with missing values coded as 0, such that the weights for these inputs are also shrunk to 0 during back-propagation and effectively no learning is done on those branches.

2.4 Joint estimation
--------------------

In addition to fitting the GLM-model to the data from each patient, we also aim to obtain a joint estimate of predictor support and effect size across in a hierarchical phylogenetic setting ([@vew023-B32]). In this analysis, we specify independent tree parameters and non-parametric coalescent processes for each patient. For the sequence evolutionary process, we specify shared predictor indicators and coefficients in the GLM-parameterisations and shared codon equilibrium frequencies. In addition, we specify hierarchical prior distributions [@vew023-B7]) to pool information for the *κ* parameters, the shape parameters of the gamma distributions for the among-site rate variation and the skygrid precision parameters. We further include patient-specific random-effects on the grand-means $\mu_{\alpha}$ and $\mu_{\beta}$ to account for absolute substitution rate differences across patients.

3. Results
==========

We apply our approach to HIV-1 *env* C2V3 sequences sampled throughout the infection of eight patients ([@vew023-B29]) in order to estimate $\alpha$ and $\beta$ and identify correlates for variation in these rates through time. We adopt an epoch structure that follows the sampling-times and consider clinical and virological parameters as well as sampling characteristics and changes in *N~e~* as predictors for the dynamics of synonymous and non-synonymous substitution rates.

We summarize independent estimates of predictor inclusion probability ($\mathbb{E}{\lbrack\delta_{kp}\rbrack}$) for each predictor and each patient as a stacked barplot in [Figure 1](#vew023-F1){ref-type="fig"}. In general, this demonstrates very little support for any predictor to consistently explain variation in either $\alpha$ or $\beta$. As an indication, the bar plot shows a vertical line at eight times the individual prior probability of predictor inclusion. For $\alpha$, only progression time and time since seroconversion yield a sum of inclusion probabilities that is somewhat higher than this value, but for both, about half of this sum is contributed by a single patient. For $\beta$, both progression time and mean CD4 show some elevation in the probability sum, but not substantial enough to attribute importance to the estimates. The only apparent consistency is that the correlated measures of progression time and mean CD4---as the former is the time at which the CD4+ T-cell counts drop below 200 cells/μl ([@vew023-B37])--- are both elevated for $\beta$.

To increase the statistical power and inform our model simultaneously by all the patient-specific data, we set up a joint analysis with shared predictor indicators and effect sizes (cfr. Section 2). [Figure 2](#vew023-F2){ref-type="fig"} summarizes the posterior inclusion probabilities and the corresponding contribution of each predictor to the dependent variable (the posterior mean and credible interval for that coefficient, conditioning on its inclusion in the GLM: that is, $({\theta_{kp}|\delta_{kp} = 1})$). We find strong support for the time since seroconversion to predict variation in $\alpha$ (posterior inclusion probability of 0.88, Bayes Factor value of 89.96), with a positive conditional effect size 0.15 (0.07, 0.22) indicating a general increase in $\alpha$ over the course of the infection. In addition, the epoch time also yields non-negligible support (posterior inclusion probability of 0.45, Bayes Factor value of 10.47), but with a negative effect size −0.08 (−0.14, −0.02), suggesting a negative correlation between $\alpha$ and epoch length. For $\beta$, we find strong support for progression time (posterior inclusion probability of 0.95, Bayes factor value of 232.2), with a positive effect size 0.15 (0.07, 0.22). Because the progression time predictor was encoded as a homogeneous estimable effect before this time point, it corresponds to higher β's before disease progression. We also note the moderate support for $\Delta N_{e}$ (posterior inclusion probability of 0.21, Bayes factor value of 3.4), with a positive effect size 0.1 (0.02, 0.19).

![Joint inclusion probabilities and conditional effect sizes on the log scale for the predictors of $\alpha$ or $\beta$. The inclusion probabilities (plots on the left) and conditional effect sizes ($\theta|\delta = 1$, plots on the right) are shared across all patients. The upper and bottom plots represent the estimates for $\alpha$ or $\beta$~,~ respectively. Thin and thick black vertical lines in the barplot present *δ* indicator expectations corresponding to Bayes factor values of 10 and 100, respectively, which following [@vew023-B16] can be interpreted as 'substantial' and 'very strong' evidence.](vew023f2p){#vew023-F2}

4. Discussion
=============

In this study, we present a novel approach to test associations between changes in substitution rates over time with changes in external predictors. The approach builds on previous developments that allow changing substitution processes through time ([@vew023-B9]; [@vew023-B1]), and also relates to ideas proposed by [@vew023-B27]). To distinguish between factors that impact neutral rates of evolution and selective dynamics, we make use of a codon substitution model parameterized in terms of absolute synonymous and non-synonymous substitution rates. Our application to within-host HIV-1 evolution demonstrates the difficulty to extract signal for changes in these parameters from individual intrahost viral populations. However, joint inference over all patients leads to support for correlates for both the synonymous and non-synonymous substitution rates.

Since the initial observation of a slowdown or stabilization in divergence accumulation in the late phase of HIV-1 infection ([@vew023-B29]), evolutionary theories have been put forward to explain these dynamics in relationship to disease progression. [@vew023-B38]) formalized the two prevailing hypotheses as 'cellular exhaustion', or the reduced availability of target cells late in infection, and 'immune relaxation', which refers to reduced selective pressure because of deteriorating immune responses. These authors used measures of synonymous and non-synonymous evolution to test these hypotheses and found strong support for a cessation of non-synonymous divergence in line with immune relaxation. By applying a local codon model to a set of trees sampled from the posterior distribution of a Bayesian relaxed clock analysis in nucleotide space, [@vew023-B21]) provided further evidence that non-synonymous divergence stabilises in some patients. The method we develop we here represents a coherent integration of codon substitution models in this Bayesian phylogenetic framework. We do not model branch-specific rate variation, but adopt epoch modelling to capture the variation in synonymous and non-synonymous rates through time. Our results also support a slowdown in non-synonymous substitution rates after progression time. Although progression time is defined as a threshold for the decline in CD4+ T-cell counts over time, we do not find a correlation with the underlying evolution of these counts. This may indicate that the immune collapse, and the associated drop in immune responses, is indeed a discrete event that occurs when the impairment rate of HIV exceeds the threshold value, as suggested by modelling studies of HIV-1 disease progression ([@vew023-B15]; [@vew023-B13]).

Interestingly, our approach also finds support for a positive correlation between synonymous substitution rates and time since seroconversion, suggesting that neutral substitution rate is gradually increasing over time in HIV-1 infection. This is in line with an experimental study that found evidence for increasing HIV-1 replication efficiency over the course of the infection ([@vew023-B33]). Increased replication rates may reduce the generation time in intrahost HIV-1 populations and lead to faster rates of neutral evolution. This has also been invoked as the explanation for the association between disease progression and synonymous substitution rates ([@vew023-B21]). The posterior synonymous substitution rates through time suggest that the increase may not always be entirely consistent throughout infection ([Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}), and in some patients this stabilizes towards the late stage of infection. This may explain why some have argued that cellular exhaustion may also sometimes be compatible with the divergence stabilization observed at the AIDS stage ([@vew023-B20]) . However, we note that synonymous rates stabilize in some patients, but do not really decrease, and the stabilization does not necessarily align with progression time ([Supplementary Fig. 2](#sup1){ref-type="supplementary-material"}). So, this may equally well reflect a natural cap on fitness increase or even a trade-off between immune escape and replication rate ([@vew023-B21]).

It may prove interesting to apply our approach to other persistent infections in the future. Intrahost HCV populations for example exhibit strong heterogeneity in the rate of molecular evolution ([@vew023-B10]), perhaps due to variation in replication rate as suggested supported by mathematical models of HCV infection kinetics ([@vew023-B25]). Together with population structure in the liver, this may induce complex chronic evolutionary patterns that are difficult to capture by simple statistics of viral genetic variation ([@vew023-B11]). Evolutionary rate variation and potential correlates have also been described in chronic HBV infections, but without making a distinction between synonymous and non-synonymous substitutions ([@vew023-B12]). We note that our model is not limited to analysis of within-host pathogen genetic data and it readily extends to other problems and predictors. By implementing the method in the publicly available BEAST software ([@vew023-B4]), it can be also connected to other models of sequence and traits evolution.

Future applications may benefit from a more coherent treatment of missing predictor data. We currently impute such predictors prior to our analysis, but it may be possible to integrate out the missing predictor values in our Bayesian inference framework. Furthermore, our model may be extended by introducing random effects for the evolutionary response variable in our GLM model. We have not pursued this in this study because the independent analyses of the patients already lacked statistical power. However, since the joint model was well informed by the data from all patients, random-effects may prove useful to explore in this context. Bayesian mixed-effects modelling has already been successfully applied in our framework ([@vew023-B7]; [@vew023-B30]).

More generally, incorporating covariates may find various uses in phylodynamic inference. We consider population size estimates as covariates for the substitution process in this study, but it may also prove interesting to model *N*~e~ as a function of potential predictors, such as CD4 counts and viral load in within-host HIV-1 dynamics. This may also be relevant for models linking coalescent theory to compartmental models in epidemiology ([@vew023-B17]; [@vew023-B34]), which can also be applied to within-host HIV-1 dynamics.

An important area for future research with Bayesian codon model implementation lies in accommodating separate among-site and among-lineage variation in synonymous and non-synonymous substitution rates. Modelling separate variation in both quantities among sites has proven crucial in accurate detection of selection pressure ([@vew023-B19]), and this relates to a rich history in the development of site-specific selection detection methods in the maximum likelihood framework ([@vew023-B18]). Inferring branch-specific variation in synonymous and non-synonymous substitution rates can also deliver important evolutionary insights ([@vew023-B28]), and this could be accommodated in our framework by connecting the codon substitution model to the uncorrelated relaxed clock models ([@vew023-B6]). However, care will need to be taken to keep the computational burden manageable as these models require an eigen-decomposition of the infinitesimal generator matrix for each branch when the tree is considered to be random, which is computationally challenging for high state-space models. Bayesian non-parametric priors specifically tailored for evolutionary problems might offer a solution because they allow identifying a limited number of rate classes, as has been demonstrated for nucleotide substitution rate variation among lineages ([@vew023-B14]). Finally, adequately modelling among-site and among-lineage variation in synonymous and non-synonymous substitution rates may also improve divergence dating in relatively deep viral phylogenies because nucleotide-based substitution models fail to account for complex patterns of spatial and temporal variability in selective pressures ([@vew023-B36]).

In conclusion, our novel approach to identify correlates synonymous and non-synonymous substitution rates confirms and refines previous hypotheses about intrahost HIV-1 evolutionary dynamics and provides the basis for promising extensions in Bayesian codon substitution modelling.

Supplementary data
==================

[Supplementary data](#sup1){ref-type="supplementary-material"} are available at *Virus Evolution* online.
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